HOPKINTON, Mass., Nov. 9 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP), a leading provider of products and services for drug discovery and development, today reported its financial results for the quarter ended September 30, 2006. Total revenues for the quarter were $26.5 million, an increase of 24% from $21.3 million in the same period in 2005. GAAP net loss for the quarter was $13.5 million ($0.33 per share) compared to a GAAP net loss of $3.9 million ($0.13 per share) in the same period in 2005. The results reflect the acquisition of Xenogen Corporation, which closed on August 9, 2006.
